Twelve‐year follow‐up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma‐derived vaccine without booster doses in children
Man‐Fung Yuen, Wei‐Ling Lim, Chi‐Chung Cheng, Shiu‐Kam Lam, Ching‐Lung Lai – 30 December 2003 – A total of 318 children were prospectively randomized in group 1 with two 5‐μg doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5‐μg doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma‐derived vaccine given at 0, 1, and 6 months. Eleven subjects with a hepatitis B surface antigen antibody (anti‐HBs) titer of less than 10 mIU/mL at 12 months were given an extra dose of vaccine and were excluded from analysis.